1. Epigenetics
  2. Epigenetic Reader Domain
  3. GSK046

GSK046 (Synonyms: iBET-BD2)

目录号: HY-136571 纯度: 98.05%
产品使用指南

GSK046 (iBET-BD2) 是一种有效,选择性和具有口服活性的 BET 蛋白 BD2 溴结构域的抑制剂,IC50 值为 264 nM (BRD2 BD2),98 nM (BRD3 BD2),49 nM (BRD4 BD2) 和 214 nM (BRDT BD2)。

MCE 的所有产品仅用作科学研究,我们不为任何个人用途提供产品和服务

GSK046 Chemical Structure

GSK046 Chemical Structure

CAS No. : 2474876-09-8

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

Size Price Stock Quantity
5 mg ¥3000 In-stock
10 mg ¥4800 In-stock
25 mg ¥9800 In-stock
50 mg ¥15500 Get quote
100 mg ¥25000 Get quote
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Top Publications Citing Use of Products
  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

Description

GSK046 (iBET-BD2) is a potent, selective and orally active bromodomain inhibitor of BD2 of the BET proteins, with IC50s of 264 nM (BRD2 BD2), 98 nM (BRD3 BD2), 49 nM (BRD4 BD2) and 214 nM (BRDT BD2), respectively[1].

IC50 & Target[1]

BRD2 BD2

264 nM (IC50)

BRD3 BD2

98 nM (IC50)

BRD4 BD2

49 nM (IC50)

BRDT BD2

214 nM (IC50)

In Vitro

GSK046 (1000 nM; refresh every three days) reduces the recruitment of BET proteins to interferon (IFN) target genes following IFN-γ stimulation. GSK046 appears to more prominently affect the recruitment of BRD2 and BRD3 compared to BRD4[1].
GSK046 (0.1-10 μM) displays a more selective phenotypic fingerprint, particularly inhibiting the production of key pro-inflammatory mediators including Th17 cytokines in the B and T cell co-culture system[1].
GSK046 (0.01-10 μM; 72 hours) does not affect the proliferative activity of human primary CD4+ T cells but still inhibits the production of effector cytokines including IFNγ, IL-17A and IL-22[1].
GSK046 (0.005-10 μM; 48 hours) impairs macrophage activation following PMA stimulation, without impacting cellular viability[1].

Cell Proliferation Assay[1]

Cell Line: Human primary CD4+ T cell
Concentration: 0.001, 0.01, 0.1, 1, 10 μM
Incubation Time: 72 hours
Result: Did not affect the proliferative activity of the cells but still inhibited the production of effector cytokines.
In Vivo

GSK046 (40 mg/kg/QD; s.c. for 14 days) has immunomodulatory activity[1].
GSK046 exhibits Cmax (C57BL6 1589, C57B16 2993 ng/mL) and terminal elimination half-lives (C57BL6 1.8, C57B16 1.9 h) following oral administration (C57BL6 10, C57B16 40 mg/kg)[1].
GSK046 exhibits Cmax (mouse 1589, rat 202 ng/mL) and terminal elimination half-lives (mouse 1.8, rat 1.4 h) following oral administration (mouse 10, rat 10 mg/kg)[1].

Animal Model: Male C57BL/6 mice (8/10-weeks-old) are injected with keyhole limpet hemocyanin (KLH)[1]
Dosage: 40 mg/kg/QD
Administration: S.c. injections for 14 days
Result: Reduced the production of anti-keyhole limpet hemocyanin (KLH) IgM and was well tolerated.
Animal Model: Female C57BL/6 mice[1]
Dosage: 10 mg/kg (Pharmacokinetic Analysis)
Administration: Oral administration
Result: Cmax (1859 ng/mL), T1/2 (1.8 h).
Animal Model: Male C57BL/6 mice[1]
Dosage: 40 mg/kg (Pharmacokinetic Analysis)
Administration: Oral administration
Result: Cmax (2993 ng/mL), T1/2 (1.9 h).
Animal Model: Female Lewis rat[1]
Dosage: 10 mg/kg (Pharmacokinetic Analysis)
Administration: Oral administration
Result: Cmax (202 ng/mL), T1/2 (1.4 h).
Molecular Weight

414.47

Formula

C₂₃H₂₇FN₂O₄

CAS No.

2474876-09-8

SMILES

O=C(N[C@H]1CC[C@H](O)CC1)C2=CC(O[C@H](C3=CC=CC=C3)C)=C(NC(C)=O)C(F)=C2

Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 83.33 mg/mL (201.05 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.4127 mL 12.0636 mL 24.1272 mL
5 mM 0.4825 mL 2.4127 mL 4.8254 mL
10 mM 0.2413 mL 1.2064 mL 2.4127 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。 -80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (5.02 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (5.02 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液
  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (5.02 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (5.02 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (5.02 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (5.02 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
References
  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

GSK046iBET-BD2GSK 046GSK-046Epigenetic Reader DomainBD2BRD2BRD3 BRD4BRDT immuno-inflammationInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
GSK046
目录号:
HY-136571
需求量: